Evidence map›Paper›PMID 30030447›Full record

ArticleNature communications2018

Drug capture materials based on genomic DNA-functionalized magnetic nanoparticles.

Carl M Blumenfeld, Michael D Schulz, Mariam S Aboian, Mark W Wilson, Terilynn Moore, Steven W Hetts, Robert H Grubbs

Abstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. 3D Printed Biosponge Adsorbers for Capturing Toxic Chemotherapy DrugsACS biomaterials science & engineering · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carl M BlumenfeldArnold and Mabel Beckman Laboratories for Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.
Michael D SchulzArnold and Mabel Beckman Laboratories for Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.
Mariam S AboianInterventional Radiology Research Laboratory, Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, 94143, USA.
Mark W WilsonInterventional Radiology Research Laboratory, Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, 94143, USA.
Terilynn MooreInterventional Radiology Research Laboratory, Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, 94143, USA.
Steven W HettsInterventional Radiology Research Laboratory, Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, 94143, USA.
Robert H GrubbsArnold and Mabel Beckman Laboratories for Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 91125, USA. rhg@caltech.edu.

Funding

Biomedical Imaging for Clinician ScientistsT32EB001631 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LINK · 2005 to 2026
$5.6M
Endovascular Chemofiltration: Optimizing Removal of Chemotherapeutics and Nanoparticles from the Blood to Reduce ToxicityR01CA194533 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HETTS, STEVEN WILLIAM · 2015 to 2019
$2.6M
NCI NIH HHS R01 CA194533NIBIB NIH HHS T32 EB001631U.S. Department of Health & Human Services | National Institutes of Health (NIH) 5T32EB001631-13U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA194533
6 · The paper itself

Abstract

Chemotherapy agents are notorious for producing severe side-effects. One approach to mitigating this off-target damage is to deliver the chemotherapy directly to a tumor via transarterial infusion, or similar procedures, and then sequestering any chemotherapeutic in the veins draining the target organ before it enters the systemic circulation. Materials capable of such drug capture are yet to be fully realized. Here, we report the covalent attachment of genomic DNA to iron-oxide nanoparticles. With these magnetic materials, we captured three common chemotherapy agents-doxorubicin, cisplatin, and epirubicin-from biological solutions. We achieved 98% capture of doxorubicin from human serum in 10 min. We further demonstrate that DNA-coated particles can rescue cultured cardiac myoblasts from lethal levels of doxorubicin. Finally, the in vivo efficacy of these materials was demonstrated in a porcine model. The efficacy of these materials demonstrates the viability of genomic DNA-coated materials as substrates for drug capture applications.

Indexed as

AnimalsAntineoplastic AgentsCisplatinDNADoxorubicinDrug Delivery SystemsHumansMagneticsMagnetite NanoparticlesMyocardiumNeoplasmsPolyethylene GlycolsRatsSwineTissue DistributionAntineoplastic AgentsCisplatinDNADoxorubicinMagnetite NanoparticlesPolyethylene Glycols

Identifiers

PMID30030447
PMCPMC6054622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.